Cargando…
Pulmonary Complications Secondary to Immune Checkpoint Inhibitors
BACKGROUND: Immune checkpoint inhibitors (ICI) have changed the landscape in the treatment of a number of cancers. Immune-related adverse events (irAEs) have emerged as a serious clinical problem with the use of ICI. METHODS: All oncology patients diagnosed with pulmonary complications secondary to...
Autores principales: | Albitar, Hasan Ahmad Hasan, Duma, Narjust, Leventakos, Konstantinos, Gallo De Moraes, Alice |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196156/ https://www.ncbi.nlm.nih.gov/pubmed/32373643 http://dx.doi.org/10.1155/2020/4928648 |
Ejemplares similares
-
Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis
por: Yang, Fang, et al.
Publicado: (2022) -
Isolated Gastritis Secondary to Immune Checkpoint Inhibitors Complicated by Superimposed Cytomegalovirus Infection
por: Nguyen, Anita H., et al.
Publicado: (2022) -
Hematologic Complications of Immune Checkpoint Inhibitors
por: Davis, Elizabeth J., et al.
Publicado: (2019) -
Hematologic complications of immune checkpoint inhibitors
por: Kroll, Michael H., et al.
Publicado: (2022) -
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
por: Cadranel, Jacques, et al.
Publicado: (2019)